日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival

辅助性利博西尼联合非甾体类芳香化酶抑制剂治疗HR阳性/HER2阴性早期乳腺癌患者:NATALEE研究疗效结果的5年随访及更新的总生存期

Crown, J; Stroyakovskii, D; Yardley, D A; Huang, C-S; Fasching, P A; Bardia, A; Chia, S; Im, S-A; Martin, M; Xu, B; Barrios, C H; Untch, M; Moroose, R; Hurvitz, S A; Hortobagyi, G N; Slamon, D J; Visco, F; Spera, G; Zarate, J P; Halligan, D; Li, Z; Loi, S

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant

MONALEESA-3试验中接受一线ribociclib联合fulvestrant治疗的HR+/HER2-晚期乳腺癌绝经后女性患者的总生存期更新

Neven, P; Fasching, P A; Chia, S; Jerusalem, G; De Laurentiis, M; Im, S-A; Petrakova, K; Bianchi, G V; Martín, M; Nusch, A; Sonke, G S; De la Cruz-Merino, L; Beck, J T; Zarate, J P; Wang, Y; Chakravartty, A; Wang, C; Slamon, D J

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer

TRIO-15 是一项多中心、开放标签的 II 期研究,旨在评估加尼妥单抗治疗复发性铂敏感卵巢癌患者的疗效和安全性。

Davidson, T M; Lebreton, C L; Hendricksen, A E Wahner; Atkinson, H J; Larson, M C; Oberg, A L; Provencher, D M; Glaspy, J A; Karlan, B Y; Slamon, D J; Konecny, G E; Ray-Coquard, I L

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

帕博西尼联合来曲唑作为雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的一线治疗方案,并进行了长期随访

Rugo, H S; Finn, R S; Diéras, V; Ettl, J; Lipatov, O; Joy, A A; Harbeck, N; Castrellon, A; Iyer, S; Lu, D R; Mori, A; Gauthier, E R; Bartlett, C Huang; Gelmon, K A; Slamon, D J

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

帕博西尼联合来曲唑对患者自述健康相关生活质量的影响:PALOMA-2试验结果

Rugo, H S; Diéras, V; Gelmon, K A; Finn, R S; Slamon, D J; Martin, M; Neven, P; Shparyk, Y; Mori, A; Lu, D R; Bhattacharyya, H; Bartlett, C H U A N G; Iyer, S; Johnston, S; Ettl, J; Harbeck, N

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.

拉帕替尼(一种新型 HER2 和 EGFR 双激酶抑制剂)在人子宫内膜癌细胞中的活性

Konecny G E, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo M Schoenberg, Toft D, Jiang S-W, Slamon D J, Podratz K C

Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group

非小细胞肺癌中细胞周期蛋白D1和表皮生长因子受体基因的扩增和过表达。肺癌研究组

Reissmann, P T; Koga, H; Figlin, R A; Holmes, E C; Slamon, D J

A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

果蝇极光激酶的同源物具有致癌性,并在人类结直肠癌中扩增。

Bischoff, J R; Anderson, L; Zhu, Y; Mossie, K; Ng, L; Souza, B; Schryver, B; Flanagan, P; Clairvoyant, F; Ginther, C; Chan, C S; Novotny, M; Slamon, D J; Plowman, G D

Efficient generation of antibodies to oncoproteins by using synthetic peptide antigens

利用合成肽抗原高效生成抗癌蛋白抗体

Tanaka, T; Slamon, D J; Cline, M J

Identification of new gene products coded from X regions of human T-cell leukemia viruses

鉴定人类T细胞白血病病毒X区编码的新基因产物

Shimotohno, K; Miwa, M; Slamon, D J; Chen, I S; Hoshino, H; Takano, M; Fujino, M; Sugimura, T